Distinctive features of severe SARS-CoV-2 pneumonia is a research paper published in Journal of Clinical Investigation (2021). On theSindex it has a DataRank of 0. It has been cited 88 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIAID NIH HHS
Grant: U19 AI135964
NIA NIH HHS
Grant: P01 AG049665
NHLBI NIH HHS
Grant: R01 HL147575
NHLBI NIH HHS
Grant: R01 HL153312
NHLBI NIH HHS
Grant: R01 HL154686
NHLBI NIH HHS
Grant: R56 HL135124
NHLBI NIH HHS
Grant: P01 HL071643
NHLBI NIH HHS
Grant: R01 HL149883
NCATS NIH HHS
Grant: UL1 TR001422
CSRD VA
Grant: I01 CX001777
NHLBI NIH HHS
Grant: P01 HL154998
NHLBI NIH HHS
Grant: R01 HL153122
National Institutes of Health
Grant: 5P01AG049665-05
Disordered Proteostasis as a Driver of Disease in the Aging Lung
National Institutes of Health
Grant: 1R56HL135124-01
Differential role of tissue-resident and monocyte-derived alveolar macrophages in the development of pulmonary fibrosis
National Institutes of Health
Grant: 9I01CX001777-08
Assessing the role of metabolism in monocyte to macrophage differentiation in pulmonary fibrosis
National Institutes of Health
Grant: 5P01HL071643-04
Pathophysiology of Alveolar Epithelial Lung Injury
National Institutes of Health
Grant: 1R01HL149883-01
Mechanisms of regulatory T cell-mediated recovery from severe influenza A virus infection
National Institutes of Health
Grant: 1R01HL154686-01
Targeting linear ubiquitination to attenuate inflammation and promote repair after IAV infection
National Institutes of Health
Grant: 5U19AI135964-02
Successful Clinical Response In Pneumonia Therapy (SCRIPT) Systems Biology Center
FWCI
4.52
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Mesenchymal stromal cell treatment improves outcomes in children with pneumonia post-hematopoietic stem cell transplantation: a retrospective cohort study
Additional file 1 of Mesenchymal stromal cell treatment improves outcomes in children with pneumonia post-hematopoietic stem cell transplantation: a retrospective cohort study
Additional file 1 of A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)
Additional file 1 of A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)
Additional file 2 of A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)
Additional file 2 of A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)
Additional file 3 of A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)
Additional file 3 of A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)